

Original Article

*First authors.

Cite this article: Yang JC, Thygesen JH, Werbeloff N, Hayes JF, Osborn DPJ (2023). Antipsychotic polypharmacy and adverse drug reactions among adults in a London mental health service, 2008–2018. *Psychological Medicine* **53**, 4220–4227. <https://doi.org/10.1017/S0033291722000952>

Received: 15 November 2021

Revised: 23 March 2022

Accepted: 24 March 2022

First published online: 29 April 2022

Keywords:

antipsychotic polypharmacy; antipsychotics; electronic health records; natural language processing

Author for correspondence:Justin C. Yang, E-mail: justin.yang@ucl.ac.uk

Antipsychotic polypharmacy and adverse drug reactions among adults in a London mental health service, 2008–2018

Justin C. Yang^{1,2,*} , Johan H. Thygesen^{1,2,3,*} , Nomi Werbeloff^{1,2,4} ,
Joseph F. Hayes^{1,2}  and David P. J. Osborn^{1,2} 

¹Division of Psychiatry, University College London, London, UK; ²Camden & Islington NHS Foundation Trust, London, UK; ³Institute of Health Informatics, University College London, London, UK and ⁴The Louis and Gabi Weisfeld School of Social Work, Bar Ilan University, Ramat Gan, Israel

Abstract

Background. Antipsychotic polypharmacy (APP) occurs commonly but it is unclear whether it is associated with an increased risk of adverse drug reactions (ADRs). Electronic health records (EHRs) offer an opportunity to examine APP using real-world data. In this study, we use EHR data to identify periods when patients were prescribed 2 + antipsychotics and compare these with periods of antipsychotic monotherapy. To determine the relationship between APP and subsequent instances of ADRs: QT interval prolongation, hyperprolactinaemia, and increased body weight [body mass index (BMI) ≥ 25].

Methods. We extracted anonymised EHR data. Patients aged 16 + receiving antipsychotic medication at Camden & Islington NHS Foundation Trust between 1 January 2008 and 31 December 2018 were included. Multilevel mixed-effects logistic regression models were used to elucidate the relationship between APP and the subsequent presence of QT interval prolongation, hyperprolactinaemia, and/or increased BMI following a period of APP within 7, 30, or 180 days respectively.

Results. We identified 35 409 observations of antipsychotic prescribing among 13 391 patients. Compared with antipsychotic monotherapy, APP was associated with a subsequent increased risk of hyperprolactinaemia (adjusted odds ratio 2.46; 95% CI 1.87–3.24) and of registering a BMI > 25 (adjusted odds ratio 1.75; 95% CI 1.33–2.31) in the period following the APP prescribing.

Conclusions. Our observations suggest that APP should be carefully managed with attention to hyperprolactinaemia and obesity.

Introduction

The potential adverse effects of antipsychotic use are well-recognised and include QT interval prolongation and torsade de pointes (a specific type of abnormal heart rhythm) (Glassman & Bigger, 2001), hyperprolactinaemia (Peuskens, Pani, Detraux, & De Hert, 2014), and weight gain (Correll, Lencz, & Malhotra, 2011). Yet, by comparison, antipsychotic polypharmacy (APP), the common practice of co-prescribing two or more antipsychotics, and the potential adverse effects arising from this practice are understudied. Previous research has not found an increased risk of mortality with APP as compared to antipsychotic monotherapy, though research has been largely heterogeneous with variations in both methodological approaches and definitions of APP (Buhagiar, Templeton, Blyth, Dey, & Giacco, 2020; Kadra et al., 2018a, 2018b; Kasteridis et al., 2019; Taipale et al., 2018). Yet, some studies have also highlighted that certain instances of polypharmacy may yield positive clinical outcomes (Bitter et al., 2008; Tiuhonen et al., 2019). The relationship between APP and QT interval appears to be inconclusive, with a meta-analysis by Takeuchi, Suzuki, Remington, and Uchida, 2015, pointing out that the evidence is scarce and inconsistent (Takeuchi et al., 2015). Some evidence suggests that APP might be linked to hyperprolactinaemia and weight gain, but again the evidence is inconclusive as some studies also find weight loss when comparing patients on APP with monotherapy (Gallego, Nielsen, De Hert, Kane, & Correll, 2012). While in certain cases there may be a clinical indication and benefit in the co-prescription of specific antipsychotic medications (e.g. better symptom control with clozapine plus another antipsychotic) (Ballon & Stroup, 2013), and mitigating metabolic side-effects with concomitant use of aripiprazole (Fleischhacker & Uchida, 2014), the general practice of APP should be the exception rather than the rule, due to the limited knowledge of potential adverse drug reactions (ADRs), and the general finding that the overall global burden of ADRs increases with APP (Gallego et al., 2012). The heterogeneity in study designs of previous studies, variations in definitions of APP, and conflicting results among prior work highlights the need for a stronger

© The Author(s), 2022. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

evidence base in this area, especially drawing upon real-world evidence to better inform clinical practice. Randomised controlled trials (RCTs), in particular, have often only examined the practice of APP with relatively brief follow-up, suggesting a need for further research (Buhagiar et al., 2020). Increasingly, routinely collected electronic health record (EHR) data have been leveraged to conduct large, high-quality studies which can address research questions which are otherwise difficult to approach using RCTs or conventional cohort designs. These studies can draw upon the wealth of real world clinical data recorded from interactions with patients, using both structured fields, which use well-defined taxonomies, as well as clinical free-text via natural language processing (NLP). In psychiatry, more specifically, these approaches have previously been used to investigate the efficacy of individual antipsychotics (Patel, Chesney, Taylor, Taylor, & McGuire, 2018), rates of long-term APP among patients with severe mental illness (Kadra et al., 2015), and risk of readmission following APP (Kadra et al., 2018a, 2018b).

Aims of the study

This study aims to use routinely collected EHR data to identify instances of APP in a large NHS mental health provider and to investigate the association between APP and the subsequent presence of three specific ADRs: prolonged corrected QT interval (QTc), hyperprolactinaemia, and increased body mass index (BMI). We hypothesised that ADRs would be associated with periods on or following APP due to the potentially additive harmful effects of taking multiple antipsychotics at the same time.

Method

Participants

Camden & Islington NHS Foundation Trust (C&I NHS FT) provides secondary mental health services to around 470 000 individuals in the London boroughs of Camden and Islington (Werbeloff et al., 2018). We examined patients aged 16 and above who had contact with C&I NHS FT between 1 January 2008 and 31 December 2018. During this period, the C&I NHS FT Clinical Record Interactive Search (CRIS) research database included anonymised information for approximately 149 000 unique patients receiving care at the Trust. We included patients who were prescribed at least one antipsychotic medication and had at least one measurement of any of the clinical outcomes of interest, namely, QTc, prolactin level, or BMI (online Supplementary Table S1).

We extracted data using CRIS (Fernandes et al., 2013), an application which allows for anonymisation of routinely collected EHR data, including both structured fields (i.e. gender and ethnicity), and unstructured fields (i.e. clinical documentation and progress notes). Research approval for the C&I NHS FT CRIS research database was obtained from the East of England - Cambridge Central Research Ethics Committee (19/EE/0210), and the project protocol was reviewed and approved by the C&I NHS FT Research Oversight Committee. Individuals who have opted out from being included in CRIS, including those who have opted out through the national data opt-out, were excluded.

Variables

Antipsychotic prescribing and polypharmacy

We identified instances of antipsychotic prescribing from clinical free text (including progress notes and letters) through the use of an NLP

application for 'medication' developed by the South London and Maudsley NHS Foundation Trust (SLaM NHS FT) Biomedical Research Centre (BRC) (Perera et al., 2016). The application used a gazetteer of generic and commercial names for all medications in use in the UK to ascertain instances where patients were reported as receiving these, with supplementary rules for ascertaining recorded dose, frequency/timing and starting/stopping statements (CRIS Natural Language Processing, n.d.). As temporal identification was important for our analysis, we only considered recorded instances of prescribed antipsychotics in the present tense. Date stamps from the source documents were used as a proxy for the prescription date. Following extraction, all antipsychotic medications were identified and multiple names for the same compound grouped together and standardised for subsequent analyses (online Supplementary Table S2). The reported precision and recall for the NLP medications identification algorithm range from 76–88% and from 69–88%, respectively, based on data from a comparable trust using EHR data at SLaM NHS FT (CRIS Natural Language Processing, n.d.). We validated the results of the NLP medications app on C&I NHS FT data by manually reviewing 100 identified matches on a set of patients, yielding a positive predictive value (PPV) of 98% and a negative predictive value (NPV) of 100%. Moreover, we observed specificity and sensitivity of 100%.

The period during which an antipsychotic was considered prescribed was defined as the contiguous period between the first date on which antipsychotic prescription was identified and the last date on which antipsychotic prescription was identified within the study period. It is possible that an antipsychotic may have continued to be prescribed to a patient following this final observation but this information was not recorded in the EHR, and thus could not be inferred for our analysis.

To distinguish true periods of APP from instances of tapering or transitioning from one antipsychotic to another, APP was defined as the co-prescription of at least two different antipsychotics for a minimum of 30 days. This threshold was determined a priori in consultation with clinicians at Camden & Islington NHS Foundation Trust who conveyed that 30 days would be a clinically meaningful ongoing co-prescription of two or more antipsychotics which would largely exclude periods of co-prescription for brief periods of agitation [e.g. pro re nata (PRN) prescribing] or during cross-titration between two different antipsychotics.

Clinical measurements and outcomes

Clinical measurements for each of QTc, prolactin and BMI were obtained for all patients aged 16 and over who were prescribed at least one antipsychotic medication between 1 January 2008 and 31 December 2018. Clinical measurements of QTc, prolactin, and BMI were identified from free-text in the EHR by developing regular expressions for the capture of each of the three measures. We used an iterative process to develop the expressions by reviewing their capture and refining the expressions to gain a PPV higher than 95%. We tested the PPV of each regular expression by manually reviewing 100 identified matches on a new unseen set of patients and found PPVs and NPVs of 100% for each of QTc, prolactin and BMI. Furthermore, our regular expressions yielded sensitivities and specificities of 100%. Regular expressions and illustrative examples of matches are shown in online Supplementary Table S2.

Prolonged QTc was defined as values above 450 and 470 ms for men and women respectively (Xiong et al., 2020). Hyperprolactinemia was defined as prolactin measurements greater than 450 mIU/L for men or 500 mIU/L for women

(Peveler *et al.*, 2008). Overweight was defined as BMI greater than or equal to 25 (Tsigos *et al.*, 2008). Online Supplementary Fig. S1 shows a schematic of how clinical measurements were classified in this study.

Exposure period

Clinically, we expect the time leading to the onset of an ADR following initiation of APP to vary depending on the specific aetiology and biological mechanism of the ADR. For instance, we expect QTc prolongation to be observable shortly after the start of APP, likely within one week (Zareba & Lin, 2003), while changes to BMI may not be observable until months after start of APP (Zhang *et al.*, 2016). Consequently, we focused on detected instances of QT interval prolongation, hyperprolactinaemia, and/or increased body weight during or following a period of APP within 7, 30, or 180 days respectively. Online Supplementary Fig. S2 illustrates how clinical measurements relate to periods of polypharmacy and exposure periods in this study. As such, individual patients could contribute clinical measurements both within and outside exposure periods and could contribute multiple measurements during exposed and unexposed periods.

Other covariates

Gender and ethnicity were extracted from structured fields. We derived the patients' Index of Multiple Deprivation (IMD) for their local area. IMD combines national census information from 38 indicators into seven domains of deprivation, yielding a single deprivation score for 32 482 lower super output areas (LSOAs) in England, each containing approximately 1500 people or 400 households. Patient's postcodes are routinely collected as part of care and this information is used to determine a patient's LSOA, prior to anonymisation. We linked IMD scores by cross-referencing each patient's LSOA to 2015 IMD national data. These were then separated by tertiles with the lowest category signifying most deprived. Individuals with missing data for these covariates were excluded from this study.

Individual patients who are seen often or are identified as high risk for adverse drug outcomes by clinicians may receive more testing or closer clinical observation than those who do not present with such risk. This may increase the likelihood of identification of ADRs in certain patient groups and risk biasing the independence of the ADR detection across the sample. To account for this, the frequency of service usage was estimated as the number of recorded clinical measurements for the study outcomes. These proxies for service usage were included in the regression analyses examining the associations with APP. We also created a variable for the length of time known to C&I NHS FT in years, but found this variable highly correlated with service usage, and thus to avoid collinearity did not use this variable in our analysis.

Analysis

Analyses were conducted using R version 4.0.2. Univariable and multivariable multilevel mixed-effects logistic regression models were used to elucidate the relationship between periods of APP and subsequent cases of ADRs, accounting for clustering of measurements within individual patients (Quené & van den Bergh, 2004).

Univariable and multivariable multilevel mixed-effects logistic regressions were conducted for each of the three ADRs (modelling individual patients as random effects, allowing for the inclusion of

individuals at multiple timepoints, both as receiving APP treatment and not, as well as having above and below threshold measures of ADR (see online Supplementary Fig. 2). For each ADR, a dichotomous variable indicated whether or not a clinical measurement represented an ADR. The primary predictor variable was whether or not the ADR was recorded during an exposure period. Multivariable regressions also included covariates to adjust for age, gender, total number of clinical measurements, ethnicity, and IMD.

Results

Table 1 describes the main characteristics of our study sample. We identified 35 409 observations of antipsychotic prescribing among 13 391 patients during the study period (1 January 2008 and 31 December 2018). This represents a total of 9.0% of the full patient population at C&I NHS FT were being prescribed antipsychotic medication at some point in that period. 3313 (24.7%) of patients prescribed antipsychotics had at least one period of APP lasting at least 30 days. The positive predictive value of the medications NLP app used to detect antipsychotic medications was 98%. Online Supplementary Fig. S3 shows the distribution of observations per individual and online Supplementary Fig. S4 shows the distribution of duration of polypharmacy (in days).

Overall, we observed 148 distinct pairwise combinations of co-prescribed antipsychotics among the 25 antipsychotics identified from the records in this study. Of the most commonly occurring pairs of co-prescribed antipsychotics, we observed 1109 instances of co-prescribed olanzapine and risperidone, 801 of aripiprazole and risperidone, and 788 of aripiprazole and olanzapine (online Supplementary Fig. S5).

Among patients who were ever prescribed antipsychotics during the study period, 3313 (24.7%) had recorded measurements of QTc, 1481 (11.1%) had measurements of prolactin, and 3863 (28.8%) had measurements of BMI. In total, we identified 15 612 measurements of QTc, 2971 measurements of prolactin level, and 11 234 measurements of BMI. The number of these measurements and whether or not these measurements represent adverse drug events are indicated in Table 2, stratified by whether or not these measurements were taken during or following APP within respective exposure periods.

The results of univariable and multivariable multilevel mixed-effects logistic regression are shown in Table 3. Controlling for all covariates, APP was associated with increased hyperprolactinaemia (adjusted odds ratio 2.46; 95% CI 1.87–3.24) within the period of APP prescribing and up to 30 days after as compared to antipsychotic monotherapy. APP was also associated with increased registration of BMI measurement in the overweight or obese range (adjusted odds ratio 1.75; 95% CI 1.33–2.31), within the period of APP prescribing and up to 6 months after as compared to antipsychotic monotherapy. We did not find evidence that APP was associated with greater frequencies of registered observations of prolonged QTc (adjusted odds ratio 0.96; 95% CI 0.73–1.27), during or within 7 days after APP as compared to antipsychotic monotherapy.

Female patients, adjusting for all covariates, had an increased odds of hyperprolactinaemia (adjusted odds ratio 2.03; 95% CI 1.49–2.77) compared to men, and fewer instances of both prolonged QTc (adjusted odds ratio 0.22; 95% CI 0.12–0.40) and overweight/obesity (adjusted odds ratio 0.51; 95% CI 0.33–0.78). As compared to White British patients and adjusting for all covariates, Black patients were more likely to experience both

Table 1. Sample demographics

	QTC		Prolactin		BMI	
	Monotherapy	Polypharmacy	Monotherapy	Polypharmacy	Monotherapy	Polypharmacy
Number of Patients	2313	1000	862	619	2748	1115
Median Number of Measurements \pm IQR	2.0 \pm 1.5	4.0 \pm 3.5	1.0 \pm 0.5	2.0 \pm 1.0	1.0 \pm 1.0	2.0 \pm 1.5
Median Age \pm IQR	47.0 \pm 14.5	44.0 \pm 10.5	44.0 \pm 12.5	43.0 \pm 10.5	47.0 \pm 12.0	44.0 \pm 10.0
Gender						
Male	1259 (54.4%)	540 (54.0%)	449 (52.1%)	316 (51.1%)	1399 (50.9%)	605 (54.3%)
Female	1054 (45.6%)	460 (46.0%)	413 (47.9%)	303 (48.9%)	1349 (49.1%)	510 (45.7%)
Ethnicity						
White British	891 (38.5%)	365 (36.5%)	323 (37.5%)	205 (33.1%)	1123 (40.9%)	377 (33.8%)
White Other	525 (22.7%)	177 (17.7%)	215 (24.9%)	107 (17.3%)	597 (21.7%)	219 (19.6%)
Asian	154 (6.7%)	78 (7.8%)	51 (5.9%)	48 (7.8%)	176 (6.4%)	98 (8.8%)
Black	491 (21.2%)	293 (29.3%)	176 (20.4%)	194 (31.3%)	534 (19.4%)	323 (29.0%)
Mixed	98 (4.2%)	42 (4.2%)	41 (4.8%)	37 (6.0%)	120 (4.4%)	48 (4.3%)
Other	154 (6.7%)	45 (4.5%)	56 (6.5%)	28 (4.5%)	198 (7.2%)	50 (4.5%)
IMD Tertile						
1 (Most Deprived)	1633 (70.6%)	725 (72.5%)	574 (66.6%)	425 (68.7%)	1924 (70.0%)	800 (71.7%)
2	562 (24.3%)	232 (23.2%)	242 (28.1%)	169 (27.3%)	666 (24.2%)	274 (24.6%)
3 (Least Deprived)	118 (5.1%)	43 (4.3%)	46 (5.3%)	25 (4.0%)	158 (5.7%)	41 (3.7%)

Characteristics for patients who received antipsychotic medication and had at least one measure of corrected QT interval (QTC), prolactin level, or body mass index (BMI) between 1 January 2008 and 31 December 2018. Numbers are stratified by measurements for QTC, prolactin level measurements, or BMI within 7, 30 or 180 days of antipsychotic polypharmacy (APP). Numbers are reported as counts (with percentage) or medians [with interquartile ranges (IQRs)].

Table 2. Clinical measurements within exposure period

Clinical Measurement	Phenotype	Measured Outside Exposure Period	Measured Within Exposure Period
QTc	Normal QTc	7525 (91.2%)	6708 (91.1%)
	Prolonged QTc	724 (8.8%)	655 (8.9%)
Prolactin	Normal	787 (55.6%)	568 (36.5%)
	Hyperprolactinaemia	629 (44.4%)	987 (63.5%)
BMI	Not Overweight or Obese	3094 (48%)	1891 (39.5%)
	Overweight or Obese	3354 (52%)	2895 (60.5%)

Number of QTc, prolactin level, and BMI measurements within normal clinical ranges and how many were defined as adverse drug outcomes (i.e. prolonged QTc, hyperprolactinaemia, or overweight/obese) and whether or not these measurements occurred during or after a period of APP within the defined exposure period. Note that individuals may have both normal or abnormal clinical measurements during either exposure or non-exposure periods, as shown in online Supplementary Fig. S1.

Table 3. Results of unadjusted and adjusted multilevel mixed-effects logistic regressions for prolonged QTc, hyperprolactinaemia, and BMI >25

	Prolonged QTc		Hyperprolactinaemia		Overweight/Obese BMI	
	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR
Antipsychotic Status						
Monotherapy	1	1	1	1	1	1
Polypharmacy	1.03 (0.78–1.36)	0.96 (0.73–1.27)	2.66* (2.03–3.48)	2.46* (1.87–3.24)	1.87* (1.43–2.45)	1.75* (1.33–2.31)
Number of Measurements	0.96 (0.92–1.00)	0.97 (0.93–1.01)	1.08* (1.02–1.15)	1.03 (0.97–1.09)	0.97 (0.93–1.01)	0.94* (0.90–0.98)
Age	1.04* (1.04–1.04)	1.03* (1.02–1.05)	0.98* (0.97–0.99)	0.98* (0.97–0.99)	1.01* (1.00–1.03)	1.02* (1.00–1.03)
Gender						
Male	1	1	1	1	1	1
Female	0.45* (0.24–0.84)	0.22* (0.12–0.40)	1.97* (1.44–2.71)	2.03* (1.49–2.77)	0.54* (0.36–0.81)	0.51* (0.33–0.78)
Ethnicity						
White British	1	1	1	1	1	1
White Other	0.81 (0.37–1.76)	0.37* (0.18–0.77)	1.42 (0.93–2.17)	1.48 (0.98–2.22)	2.62* (1.46–4.69)	1.10 (0.47–2.58)
Asian	1.03 (0.34–3.11)	0.10* (0.02–0.54)	1.28 (0.66–2.50)	1.05 (0.55–2.01)	1.38 (0.59–3.23)	6.61* (3.73–11.69)
Black	0.40* (0.17–0.91)	0.28* (0.13–0.59)	2.18* (1.45–3.28)	1.71* (1.15–2.55)	9.44* (5.23–17.03)	3.19* (1.10–9.23)
Mixed	0.47 (0.09–2.41)	0.04* (0.00–0.65)	2.25* (1.11–4.58)	1.62 (0.81–3.24)	3.56* (1.23–10.35)	1.22 (0.48–3.10)
Other	0.57 (0.14–2.37)	0.27 (0.06–1.11)	1.01 (0.51–2.00)	0.93 (0.47–1.81)	1.68 (0.66–4.24)	2.24* (1.26–3.96)
IMD Tertile						
1 (Most Deprived)	1	1	1	1	1	1
2	1.3 (0.66–2.57)	0.69 (0.36–1.34)	0.94 (0.66–1.33)	0.99 (0.71–1.39)	0.54* (0.33–0.87)	0.48* (0.29–0.80)
3 (Least Deprived)	1.48 (0.39–5.64)	0.11* (0.01–0.99)	2.22* (1.04–4.73)	2.5* (1.21–5.2)	0.13* (0.05–0.34)	0.14* (0.05–0.38)

Adjusted regressions are adjusted for number of measurements, age, gender, ethnicity, and IMD tertile. Coefficients are presented as odds ratios (ORs) with 95% confidence intervals. Statistically significant results ($p < 0.05$) are indicated with an asterisk (*).

hyperprolactinaemia (adjusted odds ratio 1.71; 95% CI 1.45–3.28) and a BMI measurement consistent with being overweight or obese (adjusted odds ratio 3.19; 95% CI 1.10–9.23).

Discussion

Key findings

Using routinely collected EHR data, we observed that approximately a quarter (24.7%) of all patients prescribed antipsychotics

from 2008–18 showed at least one period of APP at C&I NHS FT. We observed aripiprazole, olanzapine, and risperidone as among the most commonly co-prescribed antipsychotics while benperidol, lurasidone, pimozide, promazine, and ziprasidone were the least commonly co-prescribed antipsychotics. We found increased risk of hyperprolactinaemia during or up to 30 days following APP, and BMI of 25 or greater during or up to 180 days following APP. We found no association between APP and subsequent measures of prolonged QTc.

Limitations and strengths

While the extensive EHR data at C&I NHS FT have allowed us to explore the temporal relationship between APP prescribing and three commonly associated ADRs related to antipsychotic medication, there are also limitations to this approach. Firstly, all studies relying upon routinely collected data, such as EHR data, are limited to data which are collected and recorded based on routine care. This necessarily means that many measurements which would normally be included in a conventional study design may not be present in the EHR, either because they were not taken or not recorded. Moreover, because EHR data does not capture information on whether patients fill their prescriptions or whether patients actually take their medications, it may be possible, despite mentions of antipsychotics in EHR records, that patients may not actually be taking antipsychotics as prescribed. For example, in December 2020, 97 149 986 items were prescribed in England (NHS Business Services Authority, [n.d.-a](#)), whereas only 89 592 218 items (92%) were dispensed (NHS Business Services Authority, [n.d.-b](#)). Analyses of other sources of routinely collected data, such as claims or pharmacy dispensing data, can potentially provide further validation yet these methods can also be subject to inaccuracy, particularly without clinical confirmation of patient adherence to prescribed antipsychotic (s). In addition, while it is possible to examine specific dosages of prescribed antipsychotics, this was not included in our study at present due to the added complexity this would add to our analysis model. Future approaches should consider the impact of dosage with respect to both APP and monotherapy, as high-dose monotherapy may present similar risks as APP. In addition, future research, should examine the effects of medication delivery, specifically testing if oral only polypharmacy *v.* mixed oral/depot (long-acting injections) has differential impact on ADRs. In our current analysis any combination of more than one antipsychotic drug given over a period of 30 days was considered polypharmacy regardless of the mode of delivery. As well, this study did not examine the effects of APP among patients with a specific disorder or group of disorders, only among patients who were prescribed at least one antipsychotic during the study period which may include those without a history of psychosis (Hardoon et al., 2022). Importantly, this means that our findings may not necessarily hold true among those with a specific diagnosis, such as schizophrenia, and further research is necessary to elucidate this.

Moreover, this study is limited by the quality of routinely collected EHR and by the fact that this data was not collected for research purposes. As such, variations in free-text clinical documentation and notes may result in per-individual differential recording of antipsychotic prescribing, complicating attempts to identify instances through NLP. As the data are routinely, but potentially not regularly, collected, there may be gaps in recorded antipsychotic prescribing for which this study has not accounted. Prescriptions from sources external to C&I NHS FT such as GPs and/or out of borough consultations will also be missing.

Similarly, gaps in surveillance of ADRs or differential examination among patients could also affect our results, and this is a notable limitation when analysing routinely collected data from EHR. To partially account for potential bias arising from some patients receiving frequent treatment potentially undergoing more tests for ADRs than other patient groups, we included the total number of measures as a covariate in our analysis. In addition, the time to ADR onset following APP initiation may be

very short and potentially missed if measurements do not occur within a specific observation window; for instance, lack of timely electrocardiogram (ECG) measurements or their recording in the EHR may mean that some instances of QTc prolongation may have been overlooked in our analysis. Nevertheless, our findings are limited insofar that we cannot eliminate the non-random error which may be introduced from lack of randomisation. It's also unclear to what extent our observed results might be affected by carry over effects, where earlier treatments could have impacted on subsequent overweight or hyperprolactinaemia.

Importantly, our study cannot establish a causal relationship between APP and the ADRs we have examined. We cannot, for instance, rule out that patients who may have a higher risk of these ADRs, perhaps based on clinical characteristics, may also be more likely to have APP as part of their normal course of treatment. It is an important consideration for future studies to review the potential for reverse causality between the ADRs under examination and APP.

Notwithstanding, the use of routinely collected data offers the opportunity to conduct large-scale studies with real-world data without the need for extensive measurement and testing. This approach can provide initial guidance for further research and input to clinical practice, which is essential given ours and others observations that APP is common in the clinical setting (Kadra et al., 2015).

Comparison to prior findings

Our findings are broadly consistent with previous literature, although we note that prior attempts to systematically synthesise findings across heterogeneous studies investigating the safety of APP have sometimes been inconclusive (Buhagiar et al., 2020; Fleischhacker & Uchida, 2014; Gallego et al., 2012; Kadra et al., 2018a, 2018b; Patel et al., 2018; Taipale et al., 2018; Takeuchi et al., 2015). Further research utilising comparable datasets would strengthen the evidence to inform the use of APP in the clinical setting. Interestingly, we did not observe an association between APP and QTc prolongation in this study which suggests a potential need to investigate this further to understand the necessity (or lack thereof) of ECG follow-up for patients on APP. Our use of real-world EHR data shows promise in advancing the knowledge in this area.

Future directions

This study provides evidence that routinely collected EHR data can be effectively used to conduct pharmacoepidemiological studies to inform clinical practice, even in the absence of pharmacy dispensing data. The quality and volume of EHR data continues to increase, particularly as these data contribute to care quality improvement initiatives. As such, EHR research offers many opportunities to address pressing research questions which have proven difficult to address through traditional research means, such as RCTs. Future work may look at the impact of dosage, the effects of increasing number of concurrently prescribed antipsychotics during APP (e.g. the extend and effects of three or more antipsychotics being co-prescribed at one time), and/or the distinction between oral and depot prescriptions of antipsychotics. Other future research should also seek to examine specific pairs or combinations of co-prescribed antipsychotics to further elucidate the relationship between specific antipsychotics and clinical outcomes. In addition, further linkages with

complementary datasets, such as primary care records and civil mortality registers, and work to develop and validate additional NLP algorithms may permit a fuller examination of patient side effect outcomes, such as haemoglobin A1c, lipoproteins, diabetes and other important clinical outcomes not examined in this study. Furthermore, to address the non-random error which may be introduced by the lack of randomisation in analysing routinely collected data, other study designs such as stratified Cox regression or self-controlled case series may offer methodologically advantageous approaches for further analyses.

The study also contributes to the growing body of evidence that APP should be carefully managed in the clinical setting with a particular focus on the monitoring of prolactin and weight gain, and other physical health indicators, especially given the common occurrence of APP in the clinical setting.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291722000952>

Data availability. The data that support the findings of this study are available to approved researchers through Camden & Islington NHS Foundation Trust. The data are not publicly available due to restrictions on data access by the Data Controller in the interest of patient confidentiality.

Author contributions. Justin C. Yang: Methodology, software, validation, formal analysis, investigation, writing - original draft, visualisation. Johan H. Thygesen: Conceptualisation, methodology, software, validation, formal analysis, investigation, writing - original draft, visualisation. Nomi Werbeloff: Conceptualisation, validation, software, data curation. Joseph F. Hayes: Conceptualisation, methodology, writing - review & editing, supervision. David P.J. Osborn: Conceptualisation, methodology, writing review & editing, supervision, funding acquisition.

Financial support. This work was supported by the Medical Research Council (MC_PC_17216 and MR/W014386/1). David P.J. Osborn is also supported by the University College London Hospitals NIHR Biomedical Research Centre and the NIHR North Thames Applied Research Collaboration. Joseph F. Hayes is supported by UKRI grant MR/V023373/1, the University College London Hospitals NIHR Biomedical Research Centre and the NIHR North Thames Applied Research Collaboration. This funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Conflict of interest. Justin C. Yang, Johan H. Thygesen, Nomi Werbeloff, and David P.J. Osborn have no conflicts of interest to declare. Joseph F. Hayes has received consultancy fees from Wellcome Trust and juli Health.

References

- Ballon, J., & Stroup, T. S. (2013). Polypharmacy for schizophrenia. *Current Opinion in Psychiatry*, 26(2), 208–213. PubMed (23318662). <https://doi.org/10.1097/YCO.0b013e32835d9efb>.
- Bitter, I., Treuer, T., Dyachkova, Y., Martenyi, F., McBride, M., & Ungvari, G. S. (2008). Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. *European Neuropsychopharmacology*, 18(3), 170–180. <https://doi.org/10.1016/j.euroneuro.2007.08.001>.
- Buhagiar, K., Templeton, G., Blyth, H., Dey, M., & Giacco, D. (2020). Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies. *Schizophrenia Research*, 223, 18–28. <https://doi.org/10.1016/j.schres.2020.08.026>.
- Correll, C. U., Lencz, T., & Malhotra, A. K. (2011). Antipsychotic drugs and obesity. *Trends in Molecular Medicine*, 17(2), 97–107.
- CRIS Natural Language Processing. (n.d.). CRIS NLP Applications Library. Retrieved from <https://www.maudsleybrc.nihr.ac.uk/facilities/clinical-record-interactive-search-cris/cris-natural-language-processing/>.
- Fernandes, A. C., Cloete, D., Broadbent, M. T. M., Hayes, R. D., Chang, C.-K., Jackson, R. G., ... Callard, F. (2013). Development and evaluation of a de-identification procedure for a case register sourced from mental health electronic records. *BMC Medical Informatics and Decision Making*, 13(1), 71. <https://doi.org/10.1186/1472-6947-13-71>.
- Fleischhacker, W. W., & Uchida, H. (2014). Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. *The International Journal of Neuropsychopharmacology*, 17(7), 1083–1093. <https://doi.org/10.1017/S1461145712000399>.
- Gallego, J. A., Nielsen, J., De Hert, M., Kane, J. M., & Correll, C. U. (2012). Safety and tolerability of antipsychotic polypharmacy. *Expert Opinion on Drug Safety*, 11(4), 527–542.
- Glassman, A. H., & Bigger Jr, J. T. (2001). Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. *American Journal of Psychiatry*, 158(11), 1774–1782.
- Hardoon, S., Hayes, J., Viding, E., McCrory, E., Walters, K., & Osborn, D. (2022). Prescribing of antipsychotics among people with recorded personality disorder in primary care: A retrospective nationwide cohort study using The health improvement network primary care database. *BMJ Open*, 12(3), e053943. <https://doi.org/10.1136/bmjopen-2021-053943>.
- Kadra, G., Stewart, R., Shetty, H., Jackson, R. G., Greenwood, M. A., Roberts, A., ... Hayes, R. D. (2015). Extracting antipsychotic polypharmacy data from electronic health records: Developing and evaluating a novel process. *BMC Psychiatry*, 15(1), 166. <https://doi.org/10.1186/s12888-015-0557-z>.
- Kadra, G., Stewart, R., Shetty, H., MacCabe, J. H., Chang, C.-K., Kesserwani, J., ... Hayes, R. D. (2018b). Antipsychotic polypharmacy prescribing and risk of hospital readmission. *Psychopharmacology*, 235(1), 281–289. <https://doi.org/10.1007/s00213-017-4767-6>.
- Kadra, G., Stewart, R., Shetty, H., MacCabe, J. H., Chang, C. K., Taylor, D., & Hayes, R. D. (2018a). Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. *Acta Psychiatrica Scandinavica*, 138(2), 123–132. <https://doi.org/10.1111/acps.12906>.
- Kasteridis, P., Ride, J., Gutacker, N., Aylott, L., Dare, C., Doran, T., ... others. (2019). Association between antipsychotic polypharmacy and outcomes for people with serious mental illness in England. *Psychiatric Services*, 70(8), 650–656.
- NHS Business Services Authority. (n.d.-a). English Prescribing Data (EPD). Retrieved from <https://www.nhsbsa.nhs.uk/prescription-data/prescribing-data/english-prescribing-data-epd>.
- NHS Business Services Authority. (n.d.-b). NHS England Items and Fees. Retrieved from <https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/nhs-england-items-and-fees-dispensed>.
- Patel, R., Chesney, E., Taylor, M., Taylor, D., & McGuire, P. (2018). Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? *Psychological Medicine*, 48(10), 1616–1623. <https://doi.org/10.1017/S0033291717003051>.
- Perera, G., Broadbent, M., Callard, F., Chang, C. K., Downs, J., Dutta, R., ... Stewart, R. (2016). Cohort profile of the South London and Maudsley NHS foundation trust biomedical research centre (SLaM BRC) case register: Current status and recent enhancement of an electronic mental health record-derived data resource. *BMJ Open*, 6(3), 1–22. <https://doi.org/10.1136/bmjopen-2015-008721>.
- Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014). The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. *CNS Drugs*, 28(5), 421–453.
- Peveler, R. C., Branford, D., Citrome, L., Fitzgerald, P., Harvey, P. W., Holt, R. I., ... Yeomans, D. (2008). Antipsychotics and hyperprolactinaemia: Clinical recommendations. *Journal of Psychopharmacology*, 22(2_suppl), 98–103. <https://doi.org/10.1177/0269881107087346>.
- Quené, H., & van den Bergh, H. (2004). On multi-level modeling of data from repeated measures designs: A tutorial. *Speech Communication*, 43(1), 103–121. <https://doi.org/10.1016/j.specom.2004.02.004>.
- Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., ... others. (2018). Antipsychotics and mortality in a nationwide cohort of 29823 patients with schizophrenia. *Schizophrenia Research*, 197, 274–280.

- Takeuchi, H., Suzuki, T., Remington, G., & Uchida, H. (2015). Antipsychotic polypharmacy and corrected QT interval: A systematic review. *The Canadian Journal of Psychiatry*, *60*(5), 215–222.
- Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. (2019). Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. *JAMA Psychiatry*, *76*(5), 499–507.
- Tsigos, C., Hainer, V., Basdevant, A., Finer, N., Fried, M., Mathus-Vliegen, E., ... Zahorska-Markiewicz, B. (2008). Management of obesity in adults: European clinical practice guidelines. *Obesity Facts*, *1*(2), 106–116. <https://doi.org/10.1159/000126822>.
- Werbeloff, N., Osborn, D. P. J., Patel, R., Taylor, M., Stewart, R., Broadbent, M., & Hayes, J. F. (2018). The Camden & Islington research database: Using electronic mental health records for research. *PLOS ONE*, *13*(1), e0190703. <https://doi.org/10.1371/journal.pone.0190703>.
- Xiong, G. L., Pinkhasov, A., Mangal, J. P., Huang, H., Rado, J., Gagliardi, J., ... Fiedorowicz, J. G. (2020). QTC monitoring in adults with medical and psychiatric comorbidities: Expert consensus from the association of medicine and psychiatry. *Journal of Psychosomatic Research*, *135*, 110138. <https://doi.org/10.1016/j.jpsychores.2020.110138>.
- Zareba, W., & Lin, D. A. (2003). Antipsychotic drugs and QT interval prolongation. *Psychiatric Quarterly*, *74*(3), 291–306. ProQuest Central; Social Science Premium Collection (233303445; 12918603). <https://doi.org/10.1023/A:1024122706337>.
- Zhang, J.-P., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L., John, M., ... Correll, C. U. (2016). Pharmacogenetic associations of antipsychotic drug-related weight gain: A systematic review and meta-analysis. *Schizophrenia Bulletin*, *42*(6), 1418–1437. <https://doi.org/10.1093/schbul/sbw058>.